JP7141397B2 - Ｍｍｐ９インヒビター及び色素脱失障害の予防又は処置におけるその使用 - Google Patents

Ｍｍｐ９インヒビター及び色素脱失障害の予防又は処置におけるその使用 Download PDF

Info

Publication number
JP7141397B2
JP7141397B2 JP2019532076A JP2019532076A JP7141397B2 JP 7141397 B2 JP7141397 B2 JP 7141397B2 JP 2019532076 A JP2019532076 A JP 2019532076A JP 2019532076 A JP2019532076 A JP 2019532076A JP 7141397 B2 JP7141397 B2 JP 7141397B2
Authority
JP
Japan
Prior art keywords
mmp9
subject
inhibitor
depigmentation
vitiligo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019532076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504719A (ja
JP2020504719A5 (https=
Inventor
ボニファス，カーティア
セネシャル，ジュリアン
ブケドゥーニ，ネスリン
ジャックマン，クレメン
ベルナール，フランソワ－クサヴィエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire de Bordeaux
Original Assignee
Centre Hospitalier Universitaire de Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire de Bordeaux filed Critical Centre Hospitalier Universitaire de Bordeaux
Publication of JP2020504719A publication Critical patent/JP2020504719A/ja
Publication of JP2020504719A5 publication Critical patent/JP2020504719A5/ja
Application granted granted Critical
Publication of JP7141397B2 publication Critical patent/JP7141397B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019532076A 2016-12-16 2017-12-15 Ｍｍｐ９インヒビター及び色素脱失障害の予防又は処置におけるその使用 Active JP7141397B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306719 2016-12-16
EP16306719.2 2016-12-16
PCT/EP2017/083182 WO2018109222A1 (en) 2016-12-16 2017-12-15 Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder

Publications (3)

Publication Number Publication Date
JP2020504719A JP2020504719A (ja) 2020-02-13
JP2020504719A5 JP2020504719A5 (https=) 2020-12-03
JP7141397B2 true JP7141397B2 (ja) 2022-09-22

Family

ID=57680192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019532076A Active JP7141397B2 (ja) 2016-12-16 2017-12-15 Ｍｍｐ９インヒビター及び色素脱失障害の予防又は処置におけるその使用

Country Status (6)

Country Link
US (1) US10894837B2 (https=)
EP (1) EP3555138A1 (https=)
JP (1) JP7141397B2 (https=)
CN (1) CN110312737A (https=)
BR (1) BR112019012253A2 (https=)
WO (1) WO2018109222A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061351A1 (en) * 2020-09-16 2022-03-24 Incyte Corporation Topical treatment of vitiligo
US20240285497A1 (en) 2021-02-26 2024-08-29 National University Corporation Kobe University Method for evaluating an ability of a test sample to trigger a foreign body reaction in the skin, a method for screening a substance having an ability to inhibit a foreign body reaction in the skin, and an agent for inhibiting a foreign body reaction in the skin
WO2024028417A1 (en) * 2022-08-03 2024-02-08 Institut National de la Santé et de la Recherche Médicale New composition for the treatment and/or prevention of vitiligo
CN119236080A (zh) * 2024-09-29 2025-01-03 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 一种医药组合物在制备用于治疗多发性硬化药物中的应用
CN120945015B (zh) * 2025-10-17 2025-12-23 潍坊市人民医院(潍坊市公共卫生临床中心、潍坊市职业病医院) 一种适用于黑色素瘤基因检测的脱色素方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518001A (ja) 2009-02-13 2012-08-09 インディアナ ユニバーシティ リサーチ アンド テクノロジー コーポレイション Ｍｍｐ２およびｍｍｐ９を阻害する化合物および方法
WO2016023972A1 (en) 2014-08-13 2016-02-18 Calypso Biotech Sa Antibodies specific for mmp9

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59708838D1 (de) 1996-08-30 2003-01-09 Jens Peter Fuerste Spiegelselektion und spiegelevolution von nucleinsäuren
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US20040053876A1 (en) 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
US8101348B2 (en) 2002-07-10 2012-01-24 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. RNA-interference by single-stranded RNA molecules
WO2006037513A1 (en) * 2004-10-09 2006-04-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
EP2608809B1 (en) 2010-08-27 2019-05-22 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
WO2013130078A1 (en) 2012-02-29 2013-09-06 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
FR3015986A1 (fr) 2013-12-30 2015-07-03 Lvmh Rech Aptameres inhibiteurs de l'activite enzymatique de la proteine mmp-9
EP2985296A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518001A (ja) 2009-02-13 2012-08-09 インディアナ ユニバーシティ リサーチ アンド テクノロジー コーポレイション Ｍｍｐ２およびｍｍｐ９を阻害する化合物および方法
WO2016023972A1 (en) 2014-08-13 2016-02-18 Calypso Biotech Sa Antibodies specific for mmp9

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF DERMATOLOGY，2008年，Vol. 158, Issue 5，p. 941-950
Inflammatory Bowel Diseases，2016年09月，Vol. 22, No. 9，p. 2041-2057
Journal of Dermatological Science，1996年，Vol. 13，p. 30-36
Journal of Investigative Dermatology，2015年，Vol. 135，p. 1810-1819
PLOS ONE，2015年，Vol. 10, No. 5，p. 1-26
Toxicology Letters，2011年，Vol. 203, Issue 1，p. 9-19

Also Published As

Publication number Publication date
JP2020504719A (ja) 2020-02-13
CN110312737A (zh) 2019-10-08
US20190359730A1 (en) 2019-11-28
EP3555138A1 (en) 2019-10-23
BR112019012253A2 (pt) 2020-01-28
US10894837B2 (en) 2021-01-19
WO2018109222A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
JP7141397B2 (ja) Ｍｍｐ９インヒビター及び色素脱失障害の予防又は処置におけるその使用
Romagnoli et al. ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis
OuYang et al. Interleukin-4 stimulates proliferation of endometriotic stromal cells
Johnson et al. Protease-activated receptor-2 (PAR-2)-mediated NF-κB activation suppresses inflammation-associated tumor suppressor microRNAs in oral squamous cell carcinoma
Gellersen et al. Human endometrial stromal cell-trophoblast interactions: mutual stimulation of chemotactic migration and promigratory roles of cell surface molecules CD82 and CEACAM1
Lim et al. Distinct role of matrix metalloproteinase-3 in kidney injury molecule-1 shedding by kidney proximal tubular epithelial cells
Schneider et al. Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion
Kishore et al. Prostaglandin dehydrogenase is a target for successful induction of cervical ripening
US20200062862A1 (en) Methods and compositions for prognosis, diagnosis, and treatment of adam8-expressing cancer
Milara et al. IL-11 system participates in pulmonary artery remodeling and hypertension in pulmonary fibrosis
Gschwandtner et al. Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor
US20160333343A1 (en) Method of Treatment of Vascular Complications
Beltrami-Moreira et al. Redundancy of IL-1 isoform signaling and its implications for arterial remodeling
Zhang et al. XCL 1‐XCR 1 pathway promotes trophoblast invasion at maternal‐fetal interface by inducing MMP‐2/MMP‐9 activity
Berisha et al. Effect of the luteinising hormone surge on regulation of vascular endothelial growth factor and extracellular matrix-degrading proteinases and their inhibitors in bovine follicles
Fuchs et al. Fibrin fragment E potentiates TGF-β-induced myofibroblast activation and recruitment
MX2012013305A (es) Terapia combinada y metodo para evaluar resistencia al tratamiento.
Kono et al. Ras guanine nucleotide–releasing protein 4 is aberrantly expressed in the fibroblast‐like synoviocytes of patients with rheumatoid arthritis and controls their proliferation
JP2021513980A (ja) 表皮ケラチノサイトの分化の変化における使用のための容積調節性アニオンチャネルタンパク質ｌｒｒｃ８ａ
US20220249426A1 (en) Inhibitors of the sting pathway for the treatment of hidradenitis suppurativa
ES2895628T3 (es) Inhibidores de GSK3B en el tratamiento de trastornos de hipopigmentación
US9551710B2 (en) Signaling molecule involved in ultraviolet damage to skin
ES2905438T3 (es) Proteínas de la vía de señalización de WNT y usos de las mismas en el diagnóstico y tratamiento de trastornos de hipopigmentación
EP3336175B1 (en) Three-dimensional model of depigmenting disorder
Guay et al. Distinct expression of the soluble and the membrane-bound forms of interleukin-1 receptor accessory protein in the endometrium of women with endometriosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220909

R150 Certificate of patent or registration of utility model

Ref document number: 7141397

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250